Dr. Reddy's Laboratories has announced the launch of BixiBat, a drug containing elobixibat, in India for the treatment of chronic constipation. This launch follows the approval granted by the Central Drugs Standard Control Organisation (CDSCO) after reviewing Dr. Reddy's successful Phase-3 clinical trial data.
Dr. Reddy's is the first company to receive approval for and launch elobixibat in India. Elobixibat represents a new class of drugs designed to address chronic constipation by targeting bile acid reabsorption.
Mechanism of Action
Elobixibat functions by inhibiting the reabsorption of bile acids in the ileum. This inhibition increases the concentration of bile acids in the colonic lumen, which stimulates both colonic motility and fluid secretion. The increased fluid secretion and motility lead to more frequent bowel movements, irrespective of transit speed.
